难治性脓毒性休克治疗进展

Progress in Treatment of Refractory Septic Shock

高剂量血管活性药物仍难以纠正的顽固性低血压通常被称为难治性休克。目前,儿茶酚胺类药物是改善难治性脓毒性休克患者低血压、低灌注的一线药物。随着儿茶酚胺类药物使用剂量的加大,其相关并发症显著增高,影响临床疗效。针对难治性脓毒性休克患者,在儿茶酚胺类药物的基础上寻求新的临床治疗策略,以期改善该类患者低血压、低灌注状态是近年来重症医学领域的研究热点。

Refractory shock is usually defined as hypotension that cannot be corrected with high-dose of vasoactive agent. Currently,catecholamines are undoubtedly the first-line drugs to improve hypotension and hypoperfusion of refractory septic shock. Along with the increasing of doses of catecholamines,consequent drug-related-complications would significantly rise,affecting the clinical efficacy. It＇s an important and interesting subject to seek more therapeutic strategies to ameliorate hypotension and hypoperfusion of the patients suffering septic shock on the basis of catecholamines.